R
Regina K. Egan
Researcher at Harvard University
Publications - 19
Citations - 2251
Regina K. Egan is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 8, co-authored 13 publications receiving 1543 citations.
Papers
More filters
Journal ArticleDOI
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio,Francesco Iorio,Theo A. Knijnenburg,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Michael P. Menden,Michael Schubert,Nanne Aben,Nanne Aben,Emanuel Gonçalves,Syd Barthorpe,Howard Lightfoot,Thomas Cokelaer,Thomas Cokelaer,Patricia Greninger,Ewald van Dyk,Han Chang,Heshani de Silva,Holger Heyn,Xianming Deng,Regina K. Egan,Qingsong Liu,Tatiana Mironenko,Xeni Mitropoulos,Laura Richardson,Jinhua Wang,Tinghu Zhang,Sebastian Moran,Sergi Sayols,Maryam Soleimani,David Tamborero,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Petra Ross-Macdonald,Manel Esteller,Manel Esteller,Nathanael S. Gray,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +48 more
TL;DR: It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.
Journal ArticleDOI
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Sean Caenepeel,Sean P. Brown,Brian Belmontes,Gordon Moody,Kathleen S. Keegan,Danny Chui,Douglas A. Whittington,Xin Huang,Leszek Poppe,Alan C. Cheng,Mario G. Cardozo,Jonathan B. Houze,Yunxiao Li,Brian Lucas,Nick A. Paras,Xianghong Wang,Joshua Taygerly,Marc Vimolratana,Manuel Zancanella,Liusheng Zhu,Elaina Cajulis,Tao Osgood,Jan Sun,Leah J. Damon,Regina K. Egan,Patricia Greninger,Joseph McClanaghan,Jia-Nan Gong,Jia-Nan Gong,Donia M Moujalled,Giovanna Pomilio,Pedro J. Beltran,Cyril H. Benes,Andrew W. Roberts,David C.S. Huang,David C.S. Huang,Andrew H. Wei,Jude Canon,Angela Coxon,Paul E. Hughes +39 more
TL;DR: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies and the synergistic combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.
Journal ArticleDOI
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Sandra Misale,Jackson P. Fatherree,Eliane Cortez,Chendi Li,Samantha J. Bilton,Daria Timonina,David T. Myers,Dana Lee,Maria Gomez-Caraballo,Max Greenberg,Varuna Nangia,Patricia Greninger,Regina K. Egan,Joseph McClanaghan,Giovanna T. Stein,Ellen Murchie,Patrick P. Zarrinkar,Matthew R. Janes,Lian-Sheng Li,Yi Liu,Aaron N. Hata,Cyril H. Benes +21 more
TL;DR: The findings suggest that signaling adaptation can in some instances limit the efficacy of ARS1620 but combination with PI3K inhibitors can overcome this resistance.
Journal ArticleDOI
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Supriya K. Saha,John D. Gordan,Benjamin P. Kleinstiver,Phuong Vu,Mortada S. Najem,Jia-Chi Yeo,Lei Shi,Yasutaka Kato,Rebecca S. Levin,James T. Webber,Leah J. Damon,Regina K. Egan,Patricia Greninger,Ultan McDermott,Mathew J. Garnett,Roger L. Jenkins,Kimberly M. Rieger-Christ,Travis Sullivan,Aram F. Hezel,Andrew S. Liss,Yusuke Mizukami,Lipika Goyal,Cristina R. Ferrone,Andrew X. Zhu,J. Keith Joung,Kevan M. Shokat,Cyril H. Benes,Nabeel Bardeesy +27 more
TL;DR: It is found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib, with the highest sensitivity among 682 solid tumor cell lines.
Journal ArticleDOI
Differential Effector Engagement by Oncogenic KRAS
Tina L. Yuan,Arnaud Amzallag,Rachel Bagni,Ming Yi,Shervin Afghani,William E. Burgan,Nicole Fer,Leslie A. Strathern,Katie Powell,Brian Smith,Adele Waters,David G. Drubin,Ty M. Thomson,Rosy Liao,Patricia Greninger,Giovanna T. Stein,Ellen Murchie,Eliane Cortez,Regina K. Egan,Lauren V. Procter,Matthew Bess,Kwong Tai Cheng,Chih-Shia Lee,Liam C. Lee,Christof Fellmann,Robert M. Stephens,Ji Luo,Scott W. Lowe,Cyril H. Benes,Frank McCormick,Frank McCormick +30 more
TL;DR: Two major subtypes of KRAS mutant cancers of the lung, pancreas, and large intestine are identified, which reflect different KRAS effector engagement and opportunities for therapeutic intervention.